Clinical Trial

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-18; most recent amendment 2025-07-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-08-13
Trial Details
NCT Number NCT06226714
Lead Sponsor CanSino Biologics Inc.
Conditions Meningococcal Meningitis
Enrollment 840 participants
Start Date 2024-03-01
Primary Completion 2024-09-26 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-29